Macitentan

(Opsumit)

Macitentan

Drug updated on 11/13/2023

Dosage FormTablet (oral; 10mg)
Drug ClassEndothelin receptor antagonists (ERA)
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to reduce the risks of disease progression and hospitalization.

Product Monograph / Prescribing Information

Document TitleYearSource
Opsumit (macitentan) Prescribing Information.2023Actelion Pharmaceuticals US, Inc., Titusville, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines